|
Tuesday, November 19, 2019
Print Current Session:
 |
|
|
Tuesday
SESSION 5:
NEW DEVELOPMENTS IN ABDOMINAL AORTIC ANEURYSM (AAA) TREATMENT, EVAR AND EVAS (ENDOVASCULAR ANEURYSM SEALING)
|
|
| SESSION 5 SCHEDULE | |
| 1:00 PM - 1:05 PM | How And Why Is AAA Disease Different In Diabetics: How Do These Differences Impact Treatment |
|
Presenter(s):Ronald L. Dalman, MD Location: Grand Ballroom East, 3rd Floor |
|
| View Slides in PDF | |
| 1:06 PM - 1:11 PM | Update On The Nellix Graft And EVAS: Will Nellix Be A Failure Or A Phoenix Surmounting Its Problems |
|
Presenter(s):Matt M. Thompson, MD Location: Grand Ballroom East, 3rd Floor |
|
| View Slides in PDF | |
| 1:12 PM - 1:17 PM | Why Are AAA Patients Surviving More: What Is Its Impact On Screening And Size Criteria For Repair |
|
Presenter(s):Anders Wanhainen, MD, PhD / Jes S. Lindholt, MD Location: Grand Ballroom East, 3rd Floor |
|
| 1:18 PM - 1:23 PM | Value Of Metformin And Ticagrelor In Inhibiting The Growth Of Small AAAs: What Is The Long-Term Fate Of 25-29 mm Abdominal Aortas: How Many Will Become AAAs |
|
Presenter(s):Anders Wanhainen, MD, PhD Location: Grand Ballroom East, 3rd Floor |
|
| View Slides in PDF | |
| SHORT SUMMARY TOPICS (3-4 MINUTES) | |
| 1:24 PM - 1:28 PM | Influence Of Metformin On AAA Derived Cells In Culture: A Clue To How Metformin Slows AAA Growth |
|
Presenter(s):Kak Khee Yeung, MD, PhD Location: Grand Ballroom East, 3rd Floor |
|
| View Slides in PDF | |
| 1:28 PM - 1:32 PM | Update On The Value Of And Indications For Pre EVAR Lumbar And Inferior Mesenteric Artery Embolization |
|
Presenter(s):Andrej Schmidt, MD Location: Grand Ballroom East, 3rd Floor |
|
| View Slides in PDF | |
| 1:32 PM - 1:36 PM | DEBATE: There Are Several Good Reasons To Electively Repair AAAs <5.5 cm In Maximum Diameter: What Are They |
|
Presenter(s):Peter Gloviczki, MD Location: Grand Ballroom East, 3rd Floor |
|
| View Slides in PDF | |
| 1:36 PM - 1:40 PM | DEBATE: Why AAAs < 5.5 cm Should Not Be Treated Invasively: The Rupture Rate (< 1%/Year) Is Less Than Commonly Thought |
|
Presenter(s):Jonothan J. Earnshaw, FRCS Location: Grand Ballroom East, 3rd Floor |
|
| View Slides in PDF | |
| 1:40 PM - 1:45 PM | Panel Discussion |
| Moderator(s): Mark A. Adelman, MD / Michel Makaroun, MD | |
| 1:45 PM - 1:50 PM | DEBATE: Young Fit AAA Patients Have Better Long-Term Survival With Open Repair (OR) Than EVAR And Should Be Offered OR If They Need Invasive Treatment |
|
Presenter(s):Andrew W. Bradbury, MD, FRCSEd Location: Grand Ballroom East, 3rd Floor |
|
| View Slides in PDF | |
| 1:51 PM - 1:56 PM | DEBATE: Not So: Survival Is Better In Young Fit AAA Patients After EVAR Than OR |
|
Presenter(s):Hence J.M. Verhagen, MD, PhD Location: Grand Ballroom East, 3rd Floor |
|
| View Slides in PDF | |
| 1:57 PM - 2:02 PM | Why Open Repair Of AAAs Has Improving Outcomes: When Is OR Indicated And Better For Patients |
|
Presenter(s):Thomas C. Bower, MD Location: Grand Ballroom East, 3rd Floor |
|
| View Slides in PDF | |
| 2:03 PM - 2:08 PM | In AAA Patients Suitable For Both OR And EVAR Unfavorable Neck Characteristics (Short, Wide, Angulated Or Cone Shaped) Have More Adverse Outcomes And Higher Mortality After OR As Well As EVAR: From The DREAM RCT: How Should This Impact On AAA Treatment Decisions |
|
Presenter(s):Jan D. Blankensteijn, MD Location: Grand Ballroom East, 3rd Floor |
|
| View Slides in PDF | |
| 2:09 PM - 2:14 PM | Migration Patterns In Newer Lower Profile EVAR Stent-Grafts: What Are The Implications For EVAR Planning And Follow-Up |
|
Presenter(s):Colin D. Bicknell, MD, FRCS Location: Grand Ballroom East, 3rd Floor |
|
| View Slides in PDF | |
| 2:15 PM - 2:20 PM | Optimal Current Treatment For Inflammatory AAAs: When Medical; When Endo; When Open |
|
Presenter(s):Franco Grego, MD Location: Grand Ballroom East, 3rd Floor |
|
| View Slides in PDF | |
| 2:21 PM - 2:26 PM | EVAS Treated Patients (With Nellix) Have A Lower 3-Year Mortality Than EVAR Treated Patients: What Is The Mechanism And Is This Difference Restricted To Patients With AAAs >5.5 cm |
|
Presenter(s):Marc L. Schermerhorn, MD Location: Grand Ballroom East, 3rd Floor |
|
| View Slides in PDF | |
| 2:27 PM - 2:32 PM | Another View Of Why EVAS Treated Patients (With Nellix) Have A Lower Mortality Than EVAR Treated Patients: What Is The Mechanism And Is This Difference Restricted To Patients With AAAs >5.5 cm |
|
Presenter(s):Michel M.P. Reijnen, MD, PhD Location: Grand Ballroom East, 3rd Floor |
|
| View Slides in PDF | |
| 2:33 PM - 2:38 PM | Panel Discussion |
| END OF SESSION 5 | |
| previous | next |